VYNE Therapeutics Sets 1-for-50 Reverse Stock Split Ahead Of Yarrow Merger
VYNE Therapeutics (VYNE) said its board approved a 1-for-50 reverse stock split tied to its planned merger with Yarrow Bioscience. The split should cut shares from about 33.4M to about 0.7M. The merger is expected to close July 24, 2026, with the combined firm trading July 27 as Yarrow Bioscience (YARW). VYNE also set a special dividend of about $0.40242 per share.
How this was made
The 30-second read
Why it matters
The combination of reverse split, special dividend, and a near-term merger close creates multiple discrete dates that can drive trading volatility, liquidity shifts, and price-per-share distortions.
Market read
Traders should plan around the July 22 record date, July 23 expected dividend payment, July 24 ex-dividend date, July 24 merger close, and July 27 expected relisting under YARW.
What to watch
Dividend timing (record July 22, expected payment July 23, ex-dividend expected July 24) can create short-term price effects around ex-date and settlement, potentially confounding merger-related moves.
Background
VYNE is executing a planned merger with Yarrow Bioscience and is simultaneously implementing a 1-for-50 reverse stock split and a special cash dividend.
Ticker impact
VYNE approved a 1-for-50 reverse stock split tied to its planned merger with Yarrow Bioscience, changing share count materially.
Elevated volatility into the July 24 close and July 27 relisting under YARW; direction depends on merger expectations and dividend impact.
The article discloses concrete corporate actions (1-for-50 split, dividend record/payment dates, merger close and new ticker), which typically affect trading behavior even without new deal economics.
Market effects
Limited sector read-through; this is primarily a microcap corporate-action and merger execution event.
Mostly US-focused via Nasdaq Capital Market relisting and ticker change.
Low global relevance; event is company-specific.
Counterpoint
The reverse split itself may be largely mechanical, so traders may focus more on merger completion risk and any post-close financing or operating updates rather than the split ratio.
Key entities
- public_companyVYNE Therapeutics Inc.
Approved a 1-for-50 reverse stock split and special cash dividend in connection with the planned merger with Yarrow Bioscience.
- public_companyYarrow Bioscience, Inc.
Expected to become the post-merger Nasdaq-traded entity under ticker YARW starting July 27.
